Review Article
Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform
Table 4
Different cell derivatives loaded with varied cargos for cancer diagnosis and therapy.
| Refs. | Cell type | Loading method | Drugs/NPs | Drug/NP size (nm) | Cancer type | In vivo/in vitro |
| [32] | NK membrane | Coating | Gadolinium/PLGA NPs | 109 | Breast cancer | In vivo | [79] | MO membrane | Coating | Silicon particles | 3200 | Melanoma | In vivo | [80] | MA membrane | Coating | Dox/IND/Ce6/PEG/bilirubin complex | 107 | Breast cancer/melanoma | In vivo | [81] | MA membrane | Coating | PTX-albumin NPs | 138.7 | Melanoma | In vivo | [82] | MA membrane | Coating | Dexamethasone | N/A | Inflamed ear | In vivo | [83] | RBC membrane | Coating | Dox/Kirenol/phosphorous quantum dots | 10 | Cervical cancer | In vivo | [86] | Tumor cell membrane | Coating | AuNPs | 40 | N/A | In vitro | [22] | RBC sEVs | Encaps. | Free clodronate | N/A | CD47-/-model | In vivo | [95] | Blood sEVs | Between lipid layers | Free Dox | N/A | Liver cancer | In vivo | [96] | T cell sEVs | N/A | Chimeric antigen receptor | N/A | Breast cancer | In vivo | [101] | Tumor cell sEVs | Encaps. | ZnO nanocrystals | 91 | KB cancer | In vitro | [102] | Blood sEVs | Both | Dox/miRNA21 inhibitor (in), MTf/L17E (on EVs) | 106 | Glioblastoma | In vivo | [103] | RBC sEVs | Encaps. | RNA | N/A | Breast cancer | In vivo | [104] | Cancer sEVs | Encaps. | Free methotrexate | N/A | CCA | In vivo | [87] | Artificial RBC | Encaps. | Hemoglobin-dopamine complex | 100 | Breast cancer | In vivo |
|
|
Encaps. = encapsulation; BP = backpack. For other abbreviations, please refer to the abbreviation list.
|